Are Cannabinoids The Next Blockbuster Drugs? A Q&A With Jazz Pharma's CEO Bruce Cozadd

By Ben Comer, Chief Editor, Life Science Leader

Jazz Pharmaceuticals’ $7.2 billion acquisition of GW Pharmaceuticals in 2021 nearly doubled the company’s headcount and placed it at the vanguard of cannabinoid companies. With the FDA approval of Epidiolex (cannabidiol) in 2018, GW Pharma became the first company to bring a prescription drug derived from marijuana plants to market.